<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02450383</url>
  </required_header>
  <id_info>
    <org_study_id>201407810</org_study_id>
    <nct_id>NCT02450383</nct_id>
  </id_info>
  <brief_title>Comparison of Two Different Surgical Approaches To Increase Peri-Implant Mucosa Thickness</brief_title>
  <official_title>Comparison of Two Different Surgical Approaches to Increase Peri-Implant Mucosa Thickness: A Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioHorizons, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this non-inferiority trial is to determine the clinical efficacy of acellular
      dermal matrix (ADM) in the augmentation of the gum around dental implants as compared to an
      autologous gum graft (sCTG) obtained from the palate (roof of the mouth) in human adults.

      AlloDerm is regulated by the US Food and Drug Administration (FDA) as human tissue for
      transplantation. AlloDerm is processed and marketed in accordance with the FDA's requirements
      for banked human tissue (21 CFR, Part 1270 and Part 1271) and Standards for Tissue Banking of
      the American Association of Tissue Banks (AATB).

      Twenty adult subjects will be recruited who are in need of dental implant placement with
      simultaneous gum grafting to increase the thickness of the facial mucosa. Half of the
      subjects will be randomized to the ADM group and half will be randomized to the sCTG group.
      The surgical intervention will be performed according to the protocol and subjects will
      return for follow-up 2, 4, 8, and 16 weeks post-surgery for follow-up measurements of
      healing, gum thickness, subject perception of pain, and esthetic photographs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although little is known about the influence of peri-implant mucosa thickness (PMT) on
      long-term biologic outcomes, soft tissue thickness is a critical component to esthetic dental
      implant restorations. While the subepithelial connective tissue graft (sCTG) has been
      recognized as the gold standard for gingival augmentation, several studies have reported
      acellular dermal matrix (ADM) may produce similar outcomes. Healthy patients with a thin
      biotype were selected on the basis of an eligibility criteria and randomized to the control
      (sCTG) or test (ADM) group. Measurements were completed by a masked examiner at baseline and
      at implant uncovering. Patient reported outcomes were recorded, as well. A power analysis
      suggested 20 subjects be recruited. The gain in PMT at 1mm, 3mm and 5mm from the expected CEJ
      and recipient site wound dehiscence were measured and recorded in both groups at different
      time points by a calibrated, masked examiner. Patient-related outcome measures (PROMs), such
      as pain and level of satisfaction with final outcome, were also recorded for all study
      participants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Buccal Peri-implant Mucosa Thickness Between Baseline and 16 Weeks After Surgery</measure>
    <time_frame>Baseline and 16 weeks after baseline</time_frame>
    <description>Buccal mucosa thickness measurements were obtained by a calibrated, masked examiner using a custom-made stent and an endo file for precision and reproducibility between different time points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Peri-implant Keratinized Mucosa Width (Apico-coronal) at 16 Weeks After Surgery</measure>
    <time_frame>Baseline to 16 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-perceived Discomfort, Measured by VAS</measure>
    <time_frame>2 weeks</time_frame>
    <description>Patient-reported outcome measures of perceived discomfort using a visual analog scale (VAS) from 0 (no pain) to 100 (maximum pain) were recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound Healing, Measured Using a Standardized Visual Wound Healing Index</measure>
    <time_frame>2 weeks</time_frame>
    <description>Wound healing status was evaluated by the same calibrated clinician using a standardized visual wound healing index at different time points A simple wound healing scoring system including 3 categories was used: 1- uneventful wound healing, 2- slight gingival edema, erythema or discomfort, 3- poor wound healing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Tooth Loss</condition>
  <condition>Peri-implant Mucosa Defect</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autologous subepithelial connective tissue graft</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acellular Dermal Matrix</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acellular Dermal Matrix</intervention_name>
    <description>Placement of acellular dermal matrix (Alloderm®) on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Alloderm®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous subepithelial connective tissue graft</intervention_name>
    <description>Placement of autologous subepithelial connective tissue graft on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>sCTG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age: 18 to 80 years.

          -  Subjects must be able and willing to follow instructions related to the study
             procedures.

          -  Subjects must have read, understood and signed an informed consent form.

          -  At least one single-tooth edentulous site, with adjacent natural teeth, planned for
             tooth replacement therapy with an implant-supported restoration.

        Exclusion criteria:

          -  Reported allergy or hypersensitivity to any of the products to be used in the study.

          -  Severe hematologic disorders, such as hemophilia or leukemia.

          -  Active severe infectious diseases that may compromise normal healing.

          -  Liver or kidney dysfunction/failure.

          -  Currently under cancer treatment or within 18 months from completion of radio- or
             chemotherapy.

          -  Subjects with uncontrolled diabetes, defined as Hba1c &gt; 6.5% (According to the
             American Diabetes Association 2014 Guidelines)

          -  Pregnant women or nursing mothers.

          -  Smokers: Subjects who have smoked within 6 months of study onset.

          -  Concomitant medications for systemic conditions that may affect the outcomes of the
             study.

          -  Any other non-specified reason that from the point of view of the investigators will
             make a candidate not a suitable subject for the study (e.g. limited mouth opening).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Avila-Ortiz, DDS, MS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa College of Dentistry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa College of Dentistry - Craniofacial Clinical Research Center and Department of Periodontics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2015</study_first_submitted>
  <study_first_submitted_qc>May 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <results_first_submitted>May 31, 2017</results_first_submitted>
  <results_first_submitted_qc>August 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2017</results_first_posted>
  <last_update_submitted>September 16, 2017</last_update_submitted>
  <last_update_submitted_qc>September 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Gustavo Avila-Ortiz</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We are not planning on sharing IPD</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment started in January 2015 and was finalized in May 2016</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Implant placement with subepithelial connective tissue graft
Autologous subepithelial connective tissue graft</description>
        </group>
        <group group_id="P2">
          <title>Experimental</title>
          <description>Implant placement with simultaneous acellular dermal matrix graft (human allograft)
Alloderm®</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Implant placement with subepithelial connective tissue graft
Autologous subepithelial connective tissue graft</description>
        </group>
        <group group_id="B2">
          <title>Experimental</title>
          <description>Implant placement with simultaneous acellular dermal matrix graft (human allograft)
Alloderm®</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2" spread="11.0"/>
                    <measurement group_id="B2" value="59.7" spread="10.9"/>
                    <measurement group_id="B3" value="55.5" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peri-implant mucosa thickness at 1 mm</title>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.05" spread="1.28"/>
                    <measurement group_id="B2" value="2.85" spread="1.40"/>
                    <measurement group_id="B3" value="3.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Buccal Peri-implant Mucosa Thickness Between Baseline and 16 Weeks After Surgery</title>
        <description>Buccal mucosa thickness measurements were obtained by a calibrated, masked examiner using a custom-made stent and an endo file for precision and reproducibility between different time points</description>
        <time_frame>Baseline and 16 weeks after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Implant placement with subepithelial connective tissue graft
Autologous subepithelial connective tissue graft</description>
          </group>
          <group group_id="O2">
            <title>Experimental</title>
            <description>Implant placement with simultaneous acellular dermal matrix graft (human allograft)
Alloderm®</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Buccal Peri-implant Mucosa Thickness Between Baseline and 16 Weeks After Surgery</title>
          <description>Buccal mucosa thickness measurements were obtained by a calibrated, masked examiner using a custom-made stent and an endo file for precision and reproducibility between different time points</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="2.04"/>
                    <measurement group_id="O2" value="0.05" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Peri-implant Keratinized Mucosa Width (Apico-coronal) at 16 Weeks After Surgery</title>
        <time_frame>Baseline to 16 weeks after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Implant placement with subepithelial connective tissue graft
Autologous subepithelial connective tissue graft</description>
          </group>
          <group group_id="O2">
            <title>Experimental</title>
            <description>Implant placement with simultaneous acellular dermal matrix graft (human allograft)
Alloderm®</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Peri-implant Keratinized Mucosa Width (Apico-coronal) at 16 Weeks After Surgery</title>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="1.13"/>
                    <measurement group_id="O2" value="-0.45" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient-perceived Discomfort, Measured by VAS</title>
        <description>Patient-reported outcome measures of perceived discomfort using a visual analog scale (VAS) from 0 (no pain) to 100 (maximum pain) were recorded</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Implant placement with subepithelial connective tissue graft
Autologous subepithelial connective tissue graft</description>
          </group>
          <group group_id="O2">
            <title>Experimental</title>
            <description>Implant placement with simultaneous acellular dermal matrix graft (human allograft)
Alloderm®</description>
          </group>
        </group_list>
        <measure>
          <title>Patient-perceived Discomfort, Measured by VAS</title>
          <description>Patient-reported outcome measures of perceived discomfort using a visual analog scale (VAS) from 0 (no pain) to 100 (maximum pain) were recorded</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.60" spread="24.71"/>
                    <measurement group_id="O2" value="10.10" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wound Healing, Measured Using a Standardized Visual Wound Healing Index</title>
        <description>Wound healing status was evaluated by the same calibrated clinician using a standardized visual wound healing index at different time points A simple wound healing scoring system including 3 categories was used: 1- uneventful wound healing, 2- slight gingival edema, erythema or discomfort, 3- poor wound healing</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Implant placement with subepithelial connective tissue graft
Autologous subepithelial connective tissue graft</description>
          </group>
          <group group_id="O2">
            <title>Experimental</title>
            <description>Implant placement with simultaneous acellular dermal matrix graft (human allograft)
Alloderm®</description>
          </group>
        </group_list>
        <measure>
          <title>Wound Healing, Measured Using a Standardized Visual Wound Healing Index</title>
          <description>Wound healing status was evaluated by the same calibrated clinician using a standardized visual wound healing index at different time points A simple wound healing scoring system including 3 categories was used: 1- uneventful wound healing, 2- slight gingival edema, erythema or discomfort, 3- poor wound healing</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.48"/>
                    <measurement group_id="O2" value="1.90" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline intervention to 16 weeks after baseline</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Implant placement with subepithelial connective tissue graft
Autologous subepithelial connective tissue graft</description>
        </group>
        <group group_id="E2">
          <title>Experimental</title>
          <description>Implant placement with simultaneous acellular dermal matrix graft (human allograft)
Alloderm®</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Early Wound Dehiscence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gustavo Avila-Ortiz</name_or_title>
      <organization>University of Iowa</organization>
      <phone>3193357241</phone>
      <email>gustavo-avila@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

